Skip to main content
Equibles
OMER logo

OMER · Omeros Corp · Investor Relations

Track OMER — free

Use OMER with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OMER.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$18.61 +0.14 (+0.76%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Market Cap
$1.45B
Shares
72.39M
Volume · Oct 2 956.39K Avg daily vol (3M) 1.76M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-08-12 Omeros Corporation Reports Second Quarter 2026 Financial Results
2026-08-10 Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
2026-08-03 CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
2026-06-26 Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
2026-06-15 Omeros Announces Webcast Details for Annual Meeting of Shareholders
2026-05-13 Omeros Corporation Reports First Quarter 2026 Financial Results
2026-05-11 Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
2026-04-16 CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
2026-03-31 Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
2026-03-26 Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
2026-03-21 Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
2026-02-17 Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
2026-01-27 Omeros Announces First Commercial Sales of YARTEMLEA®
2025-12-26 Omeros Announces New Date for YARTEMLEA® Approval Conference Call

Past events

Date Event Type
2026-08-12 Omeros Corporation Q2 2026 Earnings Conference Call Earnings call
2026-06-18 2026 Omeros Corporation Virtual Annual Meeting of Shareholders Shareholder meeting
2026-05-13 Omeros Corporation Q1 2026 Earnings Conference Call Earnings call
2026-03-31 Q4 2025 Omeros Corporation Earnings Conference Call Earnings call
2026-01-07 Earnings conference call (announced in 8-K) Earnings call
2025-11-13 Q3 2025 Omeros Corporation Earnings Conference Call Earnings call
2025-08-14 Q2 2025 Omeros Corporation Earnings Conference Call Earnings call
2025-06-27 Omeros Corporation Virtual Annual Meeting of Shareholders Shareholder meeting
2025-05-15 Q1 2025 Omeros Corporation Earnings Conference Call Earnings call
2025-03-31 Q4 2024 Omeros Corporation Earnings Conference Call Earnings call
2024-11-13 Q3 2024 Omeros Corporation Earnings Conference Call Earnings call
2024-08-07 Q2 2024 Omeros Corporation Earnings Conference Call Earnings call
2024-06-06 Omeros Corporation Virtual Annual Shareholder Meeting Shareholder meeting
2024-05-15 Q1 2024 Omeros Corporation Earnings Conference Call Earnings call
2024-04-01 Q4 2023 Omeros Corporation Earnings Conference Call Earnings call

Source: https://investor.omeros.com/overview/default.aspx

Key facts CIK 1285819 CUSIP 682143102 13F (30d) 2 filings 2 filers Visit website Investor relations